| | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) . . . |
Ongoing |
22 Oct 2019 |
| | A study of the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension . . . |
Completed |
13 Nov 2019 |
| | A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of . . . |
Completed |
28 Sep 2020 |
| | A study to determine the safety and immunogenicity of a new vaccine for Polio in healthy infants |
Completed |
05 Mar 2020 |
| | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease . . . |
Ongoing |
18 May 2020 |
| | A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus . . . |
Pending |
27 Oct 2020 |
| | A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository For . . . |
Ongoing |
06 Jul 2020 |
| | A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer . . . |
Completed |
10 Jun 2020 |
| | An adaptive seamless randomized, double-blind, placebo controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients . . . |
Pending |
14 Jan 2020 |
| | An exploratory maintenance trial of BI 655064 in patients with lupus nephritis |
Pending |
27 May 2019 |
| | An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension . . . |
Terminated |
15 Jun 2020 |
| | An extension study to provide treatment with Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following core study TX05-03. . . . |
Ongoing |
16 Jul 2020 |
| | An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension . . . |
Ongoing |
07 Aug 2020 |
| | An immunotherapy and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV) . . . |
Ongoing |
19 Sep 2019 |
| | An international, multicentre, observational, prospective, longitudinal cohort study to assess the impact of integrated upper limb spasticity management including the use of bont-A injections on patie . . . |
Completed |
15 Jun 2020 |
| | An International, Observational, Prospective Study on Long-term Response to Botulinum toxin type A (BoNT-A) Injections in Subjects Suffering from Idiopathic Cervical Dystonia (CD) - Pharmacoeconomic I . . . |
Completed |
27 Aug 2019 |
| | An Open-Label, comparative, single dose, clinical phase 1 study to assess the safety and tolerability of Typhiod Conjugate Vaccine (EuTCV) in Healthy adults . . . |
Completed |
02 Aug 2019 |
| | Application of Stem Cells for Diabetic Foot Wounds |
Ongoing |
09 Jul 2019 |
| | ARISE: A multi-center prospective non-interventional study investigating the clinical effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in patients with type 2 diabetes mellitus in a real w . . . |
Ongoing |
29 Oct 2019 |
| | ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE |
Pending |
30 Jul 2020 |
| | Avigan Trial |
Ongoing |
11 Sep 2020 |
| | B-Clear Study |
Ongoing |
24 Sep 2020 |
| | CAIN457A2318: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability . . . |
Completed |
04 Jun 2020 |
| | Convalescent Plasma Therapy as Adjunctive Therapy for Hospitalized Patients with COVID-19: Co-CLARITY Trial . . . |
Pending |
24 Aug 2020 |
| | Copanlisib and rituximab in relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) |
Ongoing |
13 Sep 2018 |
